Aytu BioPharma sets call on fiscal 2026 Q2 results
Aytu BioPharma, Inc. announced that it issued a press release detailing its fiscal 2026 second quarter operational and financial results.
Rhea-AI Filing Summary
Aytu BioPharma, Inc. announced that it issued a press release detailing its fiscal 2026 second quarter operational and financial results. The company also scheduled a public conference call and live audio webcast on February 3, 2026 at 4:30 p.m. Eastern time to discuss these results and answer questions.
The call is accessible by webcast and telephone, with replay options available on Aytu’s website and via telephone, subject to the company’s discretion. The press release containing the results is furnished as an exhibit, but is not treated as filed for liability purposes under federal securities laws.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Aytu BioPharma (AYTU) announce in this 8-K?
Aytu BioPharma announced it issued a press release describing its fiscal 2026 second quarter operational and financial results. The company also outlined details for a same-day conference call and webcast to discuss those results and respond to questions from participants.
When is Aytu BioPharma’s fiscal 2026 Q2 earnings call scheduled?
The earnings call is scheduled for February 3, 2026 at 4:30 p.m. Eastern time. Aytu BioPharma will discuss its fiscal 2026 second quarter operational and financial results and answer questions via a publicly accessible webcast and telephone line.
How can investors access Aytu BioPharma’s fiscal 2026 Q2 conference call?
Investors can access the call via a live audio webcast through Aytu BioPharma’s website or by dialing in by telephone. Instructions for joining both the live call and the replay are provided in the press release furnished as Exhibit 99.1.
Will a replay of Aytu BioPharma’s fiscal 2026 Q2 call be available?
Yes. A replay of the conference call will be available on Aytu BioPharma’s website and via a telephone replay. The company notes that availability of these replay options is at its discretion and may be discontinued at any time.
What is included as Exhibit 99.1 in Aytu BioPharma’s 8-K?
Exhibit 99.1 contains Aytu BioPharma’s press release dated February 3, 2026. That press release announces the company’s fiscal 2026 second quarter operational and financial results and provides information for accessing the related conference call and webcast.
Is Aytu BioPharma’s fiscal 2026 Q2 press release considered filed with the SEC?
No. The company states the press release furnished as Exhibit 99.1 is not deemed filed for purposes of Section 18 of the Exchange Act. It is also not automatically incorporated by reference into other Securities Act or Exchange Act filings.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
||
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
(Address of principal executive offices, including zip code)
(720 ) 437-6580
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class
|
Trading Symbol(s)
|
Name of Each Exchange on Which Registered
|
||
|
|
|
The
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 3, 2026, Aytu BioPharma, Inc. (the “Company”) issued a press release announcing its fiscal 2026 second quarter operational and financial results. As indicated in the press release, the Company scheduled a conference call and live audio webcast for February 3, 2026, at 4:30 p.m. Eastern time to discuss the operational and financial results and to answer questions. The conference call is publicly accessible via webcast and telephone (available live and for replay), and the press release includes instructions for accessing the webcast via the Company’s website or dialing in to the call. A replay of the call will be made available after the call on the Company’s website and via a telephone replay. Availability of the call replay posted on the Company’s website and via the telephone replay is at the Company’s discretion and may be discontinued at any time. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number
|
Exhibit Description
|
|
|
99.1
|
Press Release dated February 3, 2026
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
AYTU BIOPHARMA, INC.
|
||
|
Date: February 3, 2026
|
By:
|
/s/ Ryan J. Selhorn
|
|
Ryan J. Selhorn
|
||
|
Chief Financial Officer
|
||